Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004259322 | Liver | HCC | glucose homeostasis | 137/7958 | 258/18723 | 3.59e-04 | 2.49e-03 | 137 |
GO:004345712 | Liver | HCC | regulation of cellular respiration | 33/7958 | 49/18723 | 3.86e-04 | 2.62e-03 | 33 |
GO:190371512 | Liver | HCC | regulation of aerobic respiration | 24/7958 | 33/18723 | 4.24e-04 | 2.85e-03 | 24 |
GO:003350022 | Liver | HCC | carbohydrate homeostasis | 137/7958 | 259/18723 | 4.45e-04 | 2.98e-03 | 137 |
GO:000167822 | Liver | HCC | cellular glucose homeostasis | 95/7958 | 172/18723 | 4.95e-04 | 3.24e-03 | 95 |
GO:007133112 | Liver | HCC | cellular response to hexose stimulus | 85/7958 | 153/18723 | 7.47e-04 | 4.52e-03 | 85 |
GO:007133312 | Liver | HCC | cellular response to glucose stimulus | 84/7958 | 151/18723 | 7.57e-04 | 4.56e-03 | 84 |
GO:007132612 | Liver | HCC | cellular response to monosaccharide stimulus | 85/7958 | 154/18723 | 9.78e-04 | 5.68e-03 | 85 |
GO:007132212 | Liver | HCC | cellular response to carbohydrate stimulus | 89/7958 | 163/18723 | 1.19e-03 | 6.62e-03 | 89 |
GO:00192172 | Liver | HCC | regulation of fatty acid metabolic process | 53/7958 | 93/18723 | 3.36e-03 | 1.53e-02 | 53 |
GO:00550902 | Liver | HCC | acylglycerol homeostasis | 27/7958 | 42/18723 | 3.60e-03 | 1.60e-02 | 27 |
GO:00703282 | Liver | HCC | triglyceride homeostasis | 27/7958 | 42/18723 | 3.60e-03 | 1.60e-02 | 27 |
GO:190357911 | Liver | HCC | negative regulation of ATP metabolic process | 20/7958 | 30/18723 | 6.52e-03 | 2.65e-02 | 20 |
GO:00020821 | Liver | HCC | regulation of oxidative phosphorylation | 16/7958 | 23/18723 | 8.04e-03 | 3.17e-02 | 16 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa049322 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa049323 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa049324 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
hsa04931 | Colorectum | MSS | Insulin resistance | 36/1875 | 108/8465 | 4.74e-03 | 2.01e-02 | 1.23e-02 | 36 |
hsa049325 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
hsa049311 | Colorectum | MSS | Insulin resistance | 36/1875 | 108/8465 | 4.74e-03 | 2.01e-02 | 1.23e-02 | 36 |
hsa049326 | Colorectum | MSI-H | Non-alcoholic fatty liver disease | 52/797 | 155/8465 | 4.61e-17 | 1.49e-15 | 1.25e-15 | 52 |
hsa049327 | Colorectum | MSI-H | Non-alcoholic fatty liver disease | 52/797 | 155/8465 | 4.61e-17 | 1.49e-15 | 1.25e-15 | 52 |
hsa049328 | Colorectum | FAP | Non-alcoholic fatty liver disease | 54/1404 | 155/8465 | 1.98e-08 | 6.20e-07 | 3.77e-07 | 54 |
hsa049312 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
hsa049329 | Colorectum | FAP | Non-alcoholic fatty liver disease | 54/1404 | 155/8465 | 1.98e-08 | 6.20e-07 | 3.77e-07 | 54 |
hsa049313 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
hsa049314 | Colorectum | CRC | Insulin resistance | 28/1091 | 108/8465 | 1.78e-04 | 2.37e-03 | 1.61e-03 | 28 |
hsa049315 | Colorectum | CRC | Insulin resistance | 28/1091 | 108/8465 | 1.78e-04 | 2.37e-03 | 1.61e-03 | 28 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MLXIP | SNV | Missense_Mutation | rs528028662 | c.2651C>T | p.Thr884Met | p.T884M | Q9HAP2 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
MLXIP | SNV | Missense_Mutation | novel | c.727N>G | p.Ser243Gly | p.S243G | Q9HAP2 | protein_coding | deleterious(0.01) | possibly_damaging(0.852) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
MLXIP | SNV | Missense_Mutation | | c.374C>G | p.Ser125Trp | p.S125W | Q9HAP2 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MLXIP | SNV | Missense_Mutation | | c.225N>C | p.Gln75His | p.Q75H | Q9HAP2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MLXIP | SNV | Missense_Mutation | rs202216030 | c.2362N>A | p.Glu788Lys | p.E788K | Q9HAP2 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MLXIP | SNV | Missense_Mutation | novel | c.2709N>T | p.Glu903Asp | p.E903D | Q9HAP2 | protein_coding | tolerated(0.07) | possibly_damaging(0.53) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MLXIP | SNV | Missense_Mutation | | c.1480N>T | p.His494Tyr | p.H494Y | Q9HAP2 | protein_coding | tolerated(0.06) | possibly_damaging(0.899) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MLXIP | SNV | Missense_Mutation | novel | c.1159N>T | p.Thr387Ser | p.T387S | Q9HAP2 | protein_coding | tolerated(0.59) | benign(0.009) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
MLXIP | SNV | Missense_Mutation | | c.2131C>T | p.Pro711Ser | p.P711S | Q9HAP2 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MLXIP | SNV | Missense_Mutation | | c.901N>T | p.Arg301Trp | p.R301W | Q9HAP2 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |